Antonina Kouli

Antonina Kouli

Auto-generated profile, based on publicly available information

Antonina Kouli

John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2018
Verified
Book Chapter
Open access
PDF file
AKAntonina Kouli
Antonina Kouli
KTKelli M. Torsney
Kelli M. Torsney
WKWei-Li Kuan
Wei-Li Kuan
Parkinson’s disease is an increasingly common neurodegenerative condition, which causes not only dysfunction of movement but also a broad range of nonmotor features, including mood disturbance, sleep dysfunction, autonomic dysfunction, cognitive deficits, and dementia, and neuropsychiatric symptoms. A major conundrum in this condition is understanding its striking clinical variability, which encompasses a spectrum from a benign phenotype with levodopa-responsive symptoms and minimal progression, to a malignant phenotype with rapid progression to severe gait dysfunction, falls and dementia. This book integrates the considerable expertise of a range of authors from different disciplines, from clinicians through to basic scientists, to present a comprehensive and up-to-date overview of Parkinson’s disease. In recent years, we have made significant progress in understanding the pathological and genetic basis of Parkinson’s disease and its heterogeneous forms, and the first section of the book is dedicated to reviewing this. The variable clinical features of Parkinson’s disease and its differential diagnosis are then considered. The final section provides a detailed overview of treatment approaches, including not only pharmacological therapies but also surgical therapies including deep brain stimulation and cell transplantation strategies. The combination of basic biology, clinical knowledge and therapeutics gives this book a very broad appeal. It will be of value to clinicians and health professionals caring for patients with Parkinson’s disease, as well as providing an excellent introduction for junior researchers entering the field.

3 December 2020 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
AKAntonina Kouli
Antonina Kouli
MCMarta Camacho
Marta Camacho
KAKieren Allinson
Kieren Allinson
CWCaroline H. Williams-Gray
Caroline H. Williams-Gray
Parkinson’s disease dementia is neuropathologically characterized by aggregates of α-synuclein (Lewy bodies) in limbic and neocortical areas of the brain with additional involvement of Alzheimer’s disease-type pathology. Whilst immune activation is well-described in Parkinson’s disease (PD), how it links to protein aggregation and its role in PD dementia has not been explored. We hypothesized that neuroinflammatory processes are a critical contributor to the pathology of PDD. To address this hypothesis, we examined 7 brain regions at postmortem from 17 PD patients with no dementia (PDND), 11 patients with PD dementia (PDD), and 14 age and sex-matched neurologically healthy controls. Digital quantification after immunohistochemical staining showed a significant increase in the severity of α-synuclein pathology in the hippocampus, entorhinal and occipitotemporal cortex of PDD compared to PDND cases. In contrast, there was no difference in either tau or amyloid-β pathology between the groups in any of the examined regions. Importantly, we found an increase in activated microglia in the amygdala of demented PD brains compared to controls which correlated significantly with the extent of α-synuclein pathology in this region. Significant infiltration of CD4+ T lymphocytes into the brain parenchyma was commonly observed in PDND and PDD cases compared to controls, in both the substantia nigra and the amygdala. Amongst PDND/PDD cases, CD4+ T cell counts in the amygdala correlated with activated microglia, α-synuclein and tau pathology. Upregulation of the pro-inflammatory cytokine interleukin 1β was also evident in the substantia nigra as well as the frontal cortex in PDND/PDD versus controls with a concomitant upregulation in Toll-like receptor 4 (TLR4) in these regions, as well as the amygdala. The evidence presented in this study show an increased immune response in limbic and cortical brain regions, including increased microglial activation, infiltration of T lymphocytes, upregulation of pro-inflammatory cytokines and TLR gene expression, which has not been previously reported in the postmortem PDD brain.

1 October 2019 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
AKAntonina Kouli
Antonina Kouli
CHC.B. Horne
C.B. Horne
CWC.H. Williams-Gray
C.H. Williams-Gray

3 November 2023 in Science Advances
Verified
Journal Article
Open access
RGRaquel Garza
Raquel Garza
DADiahann A. M. Atacho
Diahann A. M. Atacho
AAAnita Adami
Anita Adami
PGPatricia Gerdes
Patricia Gerdes
MVMeghna Vinod
Meghna Vinod
JJJohan Jakobsson
Johan Jakobsson
The genetic mechanisms underlying the expansion in size and complexity of the human brain remain poorly understood. Long interspersed nuclear element–1 (L1) retrotransposons are a source of divergent genetic information in hominoid genomes, but their importance in physiological functions and their contribution to human brain evolution are largely unknown. Using multiomics profiling, we here demonstrate that L1 promoters are dynamically active in the developing and the adult human brain. L1s generate hundreds of developmentally regulated and cell type–specific transcripts, many that are co-opted as chimeric transcripts or regulatory RNAs. One L1-derived long noncoding RNA, LINC01876 , is a human-specific transcript expressed exclusively during brain development. CRISPR interference silencing of LINC01876 results in reduced size of cerebral organoids and premature differentiation of neural progenitors, implicating L1s in human-specific developmental processes. In summary, our results demonstrate that L1-derived transcripts provide a previously undescribed layer of primate- and human-specific transcriptome complexity that contributes to the functional diversification of the human brain.

19 August 2021 in Brain
Verified
Journal Article
Open access
PDF file
ELEvgeniia Lobanova
Evgeniia Lobanova
DWDaniel Whiten
Daniel Whiten
FRFrancesco Simone Ruggeri
Francesco Simone Ruggeri
CTChristopher G Taylor
Christopher G Taylor
AKAntonina Kouli
Antonina Kouli
DKDavid Klenerman
David Klenerman
Aggregation of α-synuclein plays a key role in the development of Parkinson’s disease. Soluble aggregates are present not only within human brain but also the CSF and blood. Characterizing the aggregates present in these biofluids may provide insights into disease mechanisms and also have potential for aiding diagnosis. We used two optical single-molecule imaging methods called aptamer DNA-PAINT and single-aggregate confocal fluorescence, together with high-resolution atomic force microscopy for specific detection and characterization of individual aggregates with intermolecular β-sheet structure, present in the CSF and serum of 15 early stage Parkinson’s disease patients compared to 10 healthy age-matched controls. We found aggregates ranging in size from 20 nm to 200 nm, in both CSF and serum. There was a difference in aggregate size distribution between Parkinson’s disease and control groups with a significantly increased number of larger aggregates (longer than 150 nm) in the serum of patients with Parkinson’s disease. To determine the chemical composition of the aggregates, we performed aptamer DNA-PAINT on serum following α-synuclein and amyloid-β immunodepletion in an independent cohort of 11 patients with early stage Parkinson’s disease and 10 control subjects. β-Sheet aggregates in the serum of Parkinson’s disease patients were found to consist of, on average, 50% α-synuclein and 50% amyloid-β in contrast to 30% α-synuclein and 70% amyloid-β in control serum [the differences in the proportion of these aggregates were statistically significant between diseased and control groups (P = 1.7 × 10−5 for each species)]. The ratio of the number of β-sheet α-synuclein aggregates to β-sheet amyloid-β aggregates in serum extracted using our super-resolution method discriminated Parkinson’s disease cases from controls with an accuracy of 98.2% (AUC = 98.2%, P = 4.3 × 10−5). Our data suggest that studying the protein aggregates present in serum can provide information about the disruption of protein homeostasis occurring in Parkinson’s disease and warrants further investigation as a potential biomarker of disease.

1 June 2017 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Open access
GBGauri Bhosale
Gauri Bhosale
JSJenny A. Sharpe
Jenny A. Sharpe
AKAmanda Koh
Amanda Koh
AKAntonina Kouli
Antonina Kouli
GSGyorgy Szabadkai
Gyorgy Szabadkai
MDMichael R. Duchen
Michael R. Duchen
Loss of function mutations of the protein MICU1, a regulator of mitochondrial Ca2+ uptake, cause a neuronal and muscular disorder characterised by impaired cognition, muscle weakness and an extrapyramidal motor disorder. We have shown previously that MICU1 mutations cause increased resting mitochondrial Ca2+ concentration ([Ca2+]m). We now explore the functional consequences of MICU1 mutations in patient derived fibroblasts in order to clarify the underlying pathophysiology of this disorder. We propose that deregulation of mitochondrial Ca2+ uptake through loss of MICU1 raises resting [Ca2+]m, initiating a futile Ca2+ cycle, whereby continuous mitochondrial Ca2+ influx is balanced by Ca2+ efflux through the sodium calcium exchanger (NLCXm). Thus, inhibition of NCLXm by CGP-37157 caused rapid mitochondrial Ca2+ accumulation in patient but not control cells. We suggest that increased NCLX activity will increase sodium/proton exchange, potentially undermining oxidative phosphorylation, although this is balanced by dephosphorylation and activation of pyruvate dehydrogenase (PDH) in response to the increased [Ca2+]m. Consistent with this model, while ATP content in patient derived or control fibroblasts was not different, ATP increased significantly in response to CGP-37157 in the patient but not the control cells. In addition, EMRE expression levels were altered in MICU1 patient cells compared to the controls. The MICU1 mutations were associated with mitochondrial fragmentation which we show is related to altered DRP1 phosphorylation. Thus, MICU1 serves as a signal-noise discriminator in mitochondrial calcium signalling, limiting the energetic costs of mitochondrial Ca2+ signalling which may undermine oxidative phosphorylation, especially in tissues with highly dynamic energetic demands. This article is part of a Special Issue entitled: ECS Meeting edited by Claus Heizmann, Joachim Krebs and Jacques Haiech.